. Author manuscript; available in PMC: 2012 Feb 23.

Published in final edited form as: Eur J Pharm Sci. 2010 Mar 30;40(3):222–238. doi: 10.1016/j.ejps.2010.03.018

Table 4.

Compartmental pharmacokinetic parameters of sEHIs after i.v. administration in dogs (n = 3)

#	Acronym	Dose (mg kg ^-1)	Compartment	Correlation	T_1/2^a (h)	Cl^d (L/h/kg)	Vss^e (L/kg)	AUC^f (μM*min)
3	AEPU^g	0.1	1	0.98 ± 0.01	0.16 ± 0.03	5.8 ± 1.0	1.3 ± 0.2	3.6 ± 0.6
14	APAU^g	0.3	1	0.98 ± 0.02	0.6 ± 0.1	2.4 ± 0.5	2.1 ± 0.5	24 ± 5
39	t-AUCB^g	0.3	2	0.99 ± 0.01	α: 0.08 ± 0.05^b	0.4 ± 0.2	2.9 ± 1.8	160 ± 80
39	t-AUCB^g	0.3	2	0.99 ± 0.01	β: 8 ± 8^c	0.4 ± 0.2	2.9 ± 1.8	160 ± 80

terminal half life.

distribution half life.

elimination half life.

clearance.

volume of distribution at steady state.

area under the concentration (Time_{0-24 h}).

AEPU: bridging compound to previous literature; APAU: representative piperidine sEHI; t-AUCB: representative cyclohexyl ether sEHI. Note T_1/2 of AEPU can be tripled with a slow release formulation in hydroxypropylmethyl cellulose (data not shown).